Literature DB >> 8494374

Effect of oral antacids on disposition of intravenous enoxacin.

D E Nix1, M E Lebsack, M Chapelsky, A J Sedman, J Busch, A Norman.   

Abstract

The effect of an intensive aluminum-magnesium hydroxide antacid regimen (Maalox TC) on the disposition of intravenous enoxacin was studied in six male and six female volunteers. A single 400-mg dose of enoxacin was administered intravenously over 30 min on two occasions separated by a 1-week washout period. Thirty milliliters of Maalox TC was administered at -8, -2.5, -0.5, 1.5, 3.5, 5.5, 7.5, 9.5, 11.5, 13.5, and 15.5 h relative to the start of one enoxacin infusion. The enoxacin dose in which antacid was coadministered was randomly selected. Fourteen plasma samples were collected over 24 h, and urine was collected in two divided intervals over 48 h. Enoxacin concentrations in plasma and urine samples were determined by high-performance liquid chromatographic assays. The intensive antacid regimen did not change the total clearance (P = 0.058) or steady-state volume of distribution (P = 0.516) for enoxacin. However, the nonrenal clearance and half-life were significantly altered (P < 0.05). The mean nonrenal clearance increased from 13.27 +/- 3.33 to 15.68 +/- 2.35 liters/h (18.2%) following the antacid regimen. This effect of antacid is unlikely to be of clinical significance. Enoxacin may be administered intravenously, but not orally, without regard to antacid treatment.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8494374      PMCID: PMC187758          DOI: 10.1128/AAC.37.4.775

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

2.  Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.

Authors:  D E Nix; W A Watson; M E Lener; R W Frost; G Krol; H Goldstein; J Lettieri; J J Schentag
Journal:  Clin Pharmacol Ther       Date:  1989-12       Impact factor: 6.875

3.  Inhibition of norfloxacin absorption by antacids.

Authors:  D E Nix; J H Wilton; B Ronald; L Distlerath; V C Williams; A Norman
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

4.  Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline.

Authors:  V X Nguyen; D E Nix; S Gillikin; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

5.  Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys.

Authors:  S Nakamura; N Kurobe; S Kashimoto; T Ohue; Y Takase; M Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

6.  Inhibition of enoxacin absorption by antacids or ranitidine.

Authors:  T H Grasela; J J Schentag; A J Sedman; J H Wilton; D J Thomas; R W Schultz; M E Lebsack; A W Kinkel
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

  6 in total
  3 in total

1.  Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.

Authors:  S Lober; S Ziege; M Rau; G Schreiber; A Mignot; P Koeppe; H Lode
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Effect of an antacid containing magnesium and aluminum on absorption, metabolism, and mechanism of renal elimination of pefloxacin in humans.

Authors:  U Jaehde; F Sörgel; U Stephan; W Schunack
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

Review 3.  Absorption interactions with fluoroquinolones. 1995 update.

Authors:  B M Lomaestro; G R Bailie
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.